Wedgewood Introduces Compounded Molnupiravir for Feline Infectious Peritonitis Treatment
Wedgewood Pharmacy has officially added molnupiravir to its formulary, offering a new option for the treatment of Feline Infectious Peritonitis (FIP). Originally developed to treat viral infections in humans, including…
Viatris Reports Early Tender Results and Announces Increase in Pending Maximum Tender Offer
Viatris Inc. (NASDAQ: VTRS, “Viatris” or the “Company”) today announced the early results of its subsidiary Utah Acquisition Sub Inc.’s (“UAS”) previously announced cash tender offer (the “Maximum Tender Offer”).…
Blue Cross and Blue Shield of Alabama Partners with Labcorp for Improved Outpatient Lab Services
Blue Cross and Blue Shield of Alabama is dedicated to ensuring its members receive high-quality, affordable care through cost-effective healthcare providers. Starting December 1, 2024, Labcorp, a leader in comprehensive…
Zoetis Unveils First AI-Powered Cartridge-Based Hematology Analyzer
Zoetis Inc., the leading global animal health company, is set to launch its new Vetscan OptiCell™ hematology analyzer, a cutting-edge diagnostic tool that combines cartridge-based technology with AI-powered capabilities for…
FDA Approves Novartis Kisqali for Reducing Early Breast Cancer Recurrence
Novartis announced today that the US Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone…
FDA Approves OCREVUS ZUNOVO First 10-Minute Biannual Injection for Multiple Sclerosis
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS)…
Massive Bio Unveils Patient Connect: A Global Solution for Personalizing Access to Cancer Clinical Trials
Massive Bio Launches Patient Connect: A Revolutionary Platform for Global Cancer Clinical Trial Access Massive Bio, a global frontrunner in AI-driven cancer clinical trial enrollment, has unveiled Patient Connect, a…
Cellworks Predicts PARPi Benefits in Ovarian, Pancreatic, Prostate, and Triple-Negative Breast Cancers
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, has announced new findings from a study using its Cellworks Platform to predict homologous recombination deficiency…
PharmaLegacy Acquires BTS Research, Expands Preclinical Services into North America
PharmaLegacy Laboratories, a leading provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO). This acquisition marks…
ImmunoPrecise Antibodies (IPA) Announces Q1 Fiscal 2025 Financial Results and Key Business Highlights
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an AI-driven biotherapeutics research and technology company, has announced its financial results for the first quarter of fiscal 2025, ending on July 31, 2024. All…
Novatek Names Dr. Yooni Kim as Executive President for Asia Pacific to Drive Global Growth
Novotech, a global contract research organization (CRO), has announced the appointment of Dr. Yooni Kim as Executive President of Asia Pacific (APAC), effective September 1, 2024. This move reflects Novotech’s…
Tempus Announces Four Abstracts Accepted for ESMO 2024 Congress
Tempus AI, Inc. (NASDAQ: TEM), a leader in advancing precision medicine through AI technology, has announced that four of its abstracts have been accepted for presentation at the European Society…